Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

These two biotechs have a lot in common. Their differences are even more pronounced.

The CRISPR gene-editing tool can be used to silence an important hepatitis B virus gene, a proof-of-concept in vitro study suggests. "It's the first time we've seen CRISPR editing done in a hepatitis ...

An infant with a rare metabolic disease became the world’s first patient to be treated with a personalized CRISPR gene-editing treatment in a landmark study between Penn Medicine and the Children’s ...

Scientists have discovered a new CRISPR mechanism with precise activity, expanding the potential applications of the existing CRISPR toolbox. The CRISPR ‘gene scissors’ have become an important basis ...

(Nanowerk News) The Molecular Microbiology research group at the University of Alicante (UA) has identified a new enzyme with promising properties for CRISPR-Cas gene editing tools. Named AlCas12a, ...

Using prime editing, NCF1 mutation is corrected in a 19-year-old with chronic granulomatous disease, an inherited immune disorder, marking a gene therapy milestone.

Researchers at Vilnius University (Lithuania) have uncovered how the bacterial protein Cas9, better known as the CRISPR-Cas ...

Three factors will shape development of gene- and other edited therapies over the coming year and beyond. First, commercially speaking, edited therapies still see lower than expected uptake among ...

The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.

If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...